Nephraegis therapeutics
WebNephraegis Therapeutics is a biopharmaceutical company targeting acute kidney injury (AKI) through its development of a family of proprietary drug candidates that have great promise to prevent and treat AKI. Their lead compound NPH-022 is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. WebNephraegis Therapeutics is an early stage biotech developing a series of kidney therapies. The lead New Medical Entity, NPH-022, has been significantly de-risked for a program at this stage. Nephraegis welcomes inquiries from venture capital groups, angel investors, incubators, and companies interested in partnering.
Nephraegis therapeutics
Did you know?
WebDec 13, 2024 · Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI) Read more > December 10, 2024 Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups. WebNephraegis Therapeutics is a biopharmaceutical company targeting acute kidney injury (AKI) through its development of a family of proprietary drug candidates that have great …
WebNephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI). Lists Featuring This Company. Edit Lists Featuring … WebNephraegis Therapeutics is an early stage biotechnology company focused on patients with renal disease. Our initial effort is to prevent Acute Kidney Injury (AKI) ...
WebNephraegis Therapeutics Overview. Founded Year 2024. Location Lake Forest, United States. Company Stage Seed. Last Funding Round Undisclosed, Seed, May 12, 2024. … WebPleased to share the launch of a new Section in Frontiers in Physiology - Reproductive and Mating Physiology led by Prof Trish Berger, University of California, Davis This Section is dedicated to ...
WebNephraegis Therapeutics. Hospitals & Physicians Clinics · Illinois, United States · <25 Employees . Nephraegis Therapeutics is a biopharmaceutical company targeting acute …
WebMay 12, 2024 · Nephraegis Therapeutics has raised a total of — in funding over 1 round. This was a Seed round raised on May 12, 2024 . Nephraegis Therapeutics is funded by Xontogeny . inclusive learning in the philippinesWebAug 2, 2024 · In May 2024, Nephraegis Therapeutics, developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) launched with a seed investment from Xontogeny, LLC to advance their lead compound through ... inclusive learning managerWebCreating therapeutics to protect kidney function. Home Team News ☎ (815) 687-6843 ... inclusive learning opportunitiesWebNephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI). inclusive learning experienceWebMay 12, 2024 · Nephraegis Therapeutics . Announced Date May 12, 2024; Funding Type Seed; Funding Stage Seed; Lead Investors. Edit Lead Investors Section. Xontogeny Xontogeny is a biotech aggregator. Investors. Edit Investors Section. Number of Investors 1. Number of Partner Investors 2. Investor Name . Partners inclusive learning systemWebNephraegis Therapeutics is a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI). inclusive left-wing alternatives to tribalismWebNephraegis Therapeutics is a biopharmaceutical company targeting acute kidney injury (AKI) through its development of a family of proprietary drug candidates that have great … inclusive learning strategies